Efficacy

Zepzelca (Lurbinectedin) for Small Cell Lung Cancer

Zepzelca (lurbinectedin) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic small cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy. Lurbinectedin is a selective inhibitor of oncogenic transcription and modulates the tumor microenvironment. Its efficacy was evaluated in a multicenter, single-arm, open-label clinical trial that included a cohort of patients with SCLC who had disease progression on or after platinum-based chemotherapy. The main efficacy outcome measures were overall response rate (ORR) and duration of response (DOR).

The results demonstrated that Zepzelca achieved an ORR of 35% with a median DOR of 5.3 months. These findings suggest that Zepzelca can provide a clinically meaningful response in a subset of patients with metastatic SCLC who have limited treatment options after failure of first-line therapy. However, it is important to note that responses may vary among patients, and not all individuals may experience the same level of benefit from this treatment.

Rybrevant (Amivantamab-vmjw) for Non-Small Cell Lung Cancer

Rybrevant (amivantamab-vmjw) is another FDA-approved therapy, indicated for the treatment of adult patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Amivantamab-vmjw is a bispecific antibody that targets both EGFR and MET receptors. The approval of Rybrevant was based on the results of a multicenter, non-randomized, open-label, multicohort clinical trial. The efficacy of Rybrevant was primarily measured by ORR and DOR.

In the clinical trial, Rybrevant demonstrated an ORR of 40% in patients with NSCLC harboring EGFR exon 20 insertion mutations. The median DOR was 11.1 months, indicating that the responses achieved with this therapy are durable for a significant period. These results underscore the potential of Rybrevant as a targeted therapy for a specific subset of NSCLC patients who previously had limited treatment options. However, similar to other therapies, individual responses to Rybrevant can vary, and not all patients will respond to treatment.